Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vsother available dosage forms

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 12, 2012, Pages 631-636

  Yue, C S ^a   Scarsi, C ^b   Ducharme, M P ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b IBSA Institut Biochimique SA   (Switzerland)

Author keywords

capsule; equivalence; levothyroxine; pharmacokinetics; solution; tablet

Indexed keywords

LEVO T; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN CELL; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT PRECISION; NORMAL HUMAN; OUTCOME ASSESSMENT; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CAPSULES; CROSS-OVER STUDIES; DOSAGE FORMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL SOLUTIONS; RADIOIMMUNOASSAY; REPRODUCIBILITY OF RESULTS; TABLETS; THYROXINE; YOUNG ADULT;

EID: 84871846714     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1329951     Document Type: Article

References (21)

1. Wartofsky L. Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opinion on Pharmacotherapy: 2002; 3 06 727 732 (Pubitemid 34649702)
2. AHFS Drug Information® Bethesda, MD American Society of Health-System Pharmacists, Inc: 2011
3. th ed McGraw-Hill Companies: 2011
4. th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2005
5. Liwanpo L., Hershman J. M. Conditions and drugs interfering with thyroxine absorption. Best Practice & Research Clinical Endocrinology & Metabolism: 2009; 23 781 792
6. th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2005
7. Yannovits N., Zintzaras E., Pouli A. et al. A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics: 2006; 31 02 73 78 (Pubitemid 44166284)
8. Colucci P., DAngelo P., Mautone G. et al. Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Therapeutic Drug Monitoring: 2011; 33 03 355 361
9. Dunn O. J. Multiple comparisons using rank sums. Technometrics: 1964; 6 241 252
10. Gibaldi M. Bioequivalence of thyroid preparations: the final word? The AAPS Journal: 2005; 7 01 E59 E60
11. Colucci P., Turgeon J., Ducharme M. P. How critical is the duration of the sampling scheme for the determination of half-life, characterization of exposure and assessment of bioequivalence? Journal of Pharmacy & Pharmaceutical Sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques: 2011; 14 02 217 226
12. Lilja J. J., Laitinen K., Neuvonen P. J. Effects of grapefruit juice on the absorption of levothyroxine. British Journal of Clinical Pharmacology: 2005; 60 03 337 341 (Pubitemid 41224144)
13. Siraj E. S., Gupta M. K., Reddy S. S. Raloxifene causing malabsorption of levothyroxine. Archives of Internal Medicine: 2003; 163 11 1367 1370 (Pubitemid 36676204)
14. Singh N., Singh P. N., Hershman J. M. Effect of calcium carbonate on the absorption of levothyroxine. JAMA: the Journal of the American Medical Association: 2000; 283 21 2822 2825 (Pubitemid 30387827)
15. Campbell N. R., Hasinoff B. B., Stalts H. et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Annals of Internal Medicine: 1992; 117 12 1010 1013
16. Sherman S. I., Tielens E. T., Ladenson P. W. Sucralfate causes malabsorption of L-thyroxine. The American Journal of Medicine: 1994; 96 06 531 535 (Pubitemid 24184438)
17. Havrankova J., Lahaie R. Levothyroxine binding by sucralfate. Annals of Internal Medicine: 1992; 117 05 445 446
18. Sperber A. D., Liel Y. Evidence for Interference With the Intestinal Absorption of Levothyroxine Sodium by Aluminum Hydroxide. Archives of Internal Medicine: 1992; 152 01 183 184
19. Northcutt R. C., Stiel J. N., Hollifield J. W. et al. The influence of cholestyramine on thyroxine absorption. JAMA: the Journal of the American Medical Association: 1969; 208 10 1857 1861
20. Liel Y., Sperber A. D., Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. The American Journal of Medicine: 1994; 97 04 363 365 (Pubitemid 24313096)
21. Liel Y., Harman-Boehm I., Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. The Journal of Clinical Endocrinology and Metabolism: 1996; 81 02 857 859 (Pubitemid 26055713)